Modulating gut microbiota using nanotechnology to increase anticancer efficacy of the treatments

Abduladheem Turki Jalil,Shahad N. Thabit,Zaman Kareem Hanan,Mohammed Qasim Alasheqi,Abdul Kareem J. Al-Azzawi,Rahman S. Zabibah,Ali A. Fadhil
DOI: https://doi.org/10.1007/s13233-023-00168-z
IF: 2.127
2023-05-05
Macromolecular Research
Abstract:Recent clinical and pathological evidence has implicated the gut microbiota as an interplay for regulating human body homeostasis, influencing conditions ranging from cancer and dementia to obesity and social behavior. It has the potential to influence cancer prognosis and the results of cancer therapies such as chemotherapy, radiation therapy, and immunotherapy. A growing body of evidence suggests that modulating the gut microbiota can improve the efficacy of anticancer drugs. Nanomedicine has emerged as one of the most promising technologies for modernizing traditional approaches. Accordingly, specific attention has been grabbed toward using nanomaterials to modulate the gut microbiota to enhance the anticancer treatment efficacy. The critical roles of gut microbiota in carcinogenesis, cancer progression, and various cancer therapies are first introduced in this review. Following that, nanomedicine advances that improve cancer therapy efficacy by modulating or engineering gut microbiota are highlighted. Finally, the challenges and opportunities of using nanomedicine to target gut microbiota for cancer prevention and treatment are briefly discussed. Although there are some review papers in this concept, but there are room for further clarification to shed light on the way cross-talk between gut microbiota and cancer and, more specifically, modulating effects and emerging roles of nanomaterials. Graphical Nanomaterials crosstalk with gut microbiome
polymer science
What problem does this paper attempt to address?